Glucagon-Like-Peptide-1 receptor agonists (GLP-1 RA) are a class of medications originally developed to treat type 2 diabetes, but have since gained widespread attention for their effects on weight loss and metabolic health. Emerging research suggests that GLP1-Receptor Agonists could be supportive in managing inflammatory symptoms associated with Mast Cell Activation Syndrome (MCAS). Although research is currently limited, Anna talks about what we know so far and her experience with clients taking these drugs in clinical practice.
Website: http://annamarsh.co.uk/
Instagram: https://www.instagram.com/anna_marsh_nutrition/
Research Paper: https://www.sciencedirect.com/science/article/abs/pii/S0002962925011061
Take the Fatigue Recovery Quiz: https://app.annamarsh.co.uk/quiz
New Nurturing Resilience Membership: https://annamarsh.co.uk/nurturing-resilience/
Shownotes Anna shares some updates from her recent trip to South Africa as well as a discussion about how to approach the New Year...
Shownotes The festive season can be a challenging time for so many reasons; more triggers, complex family dynamics, more commitments, late nights and increased...
Shownotes The cell danger response (CDR) is the body’s universal and ancient response to threat. It offers a framework from which we can begin...